If the Pharmaceutical Industry were to align to broad metrics that objectively state each product’s “Safety
Rating” two things would happen. First, Life Sciences companies would refocus dramatically on safety (followed by
outcomes). Second, companies that have the highest aggregate “Safety Rating” would enjoy a significant competitive
advantage. To achieve and maintain a high safety rating, the role of Safety officer needs to be elevated to the C –Suite.
Keywords: Drug safety, safety rating, disruptions, ‘chief safety officer’.
Rights & PermissionsPrintExport